Pharmacokinetics and pharmacodynamics of a novel orally active angiotensin converting enzyme inhibitor (HOE 498) in healthy subjects |
| |
Authors: | P. U. Witte R. Irmisch P. Hajdú H. Metzger |
| |
Affiliation: | (1) Hoechst AG, Frankfurt/Main, Federal Republic of Germany |
| |
Abstract: | Summary The pharmacokinetics and pharmacodynamics of the angiotensin converting enzyme inhibitor HOE 498 were investigated in 10 healthy normotensive male subjects. Serum levels of the active metabolite M 1 (dicarboxylic acid) of HOE 498 were measured by HPLC up to 14 days after a single oral dose of 10 m g HOE 498. Peak serum concentration of M 1 between 5–50 ng/ml was observed 1.5–3.0 h after administration. The serum concentration-time curve of M 1 was polyphasic and exhibited a prolonged terminal phase with a half-life of approximately 110 h. Despite the long terminal half-life M 1 could not be detected in urine later than 72 h after administration. The activity of the angiotensin converting enzyme in plasma was completely suppressed for up to 12 h, and 72 h after dosing 50% inhibition of the enzyme was still observed. |
| |
Keywords: | HOE 498 ACE inhibitor pharmacokinetics pharmacodynamics urinary excretion |
本文献已被 SpringerLink 等数据库收录! |